Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer

•In men with new metastatic hormone sensitive prostate cancer (mHSPC), time from definitive therapy (DT) to initiation of androgen deprivation therapy (ADT) (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2019-06, Vol.37 (6), p.352.e19-352.e24
Hauptverfasser: Hahn, Andrew W., Stenehjem, David D., Alex, Anitha B., Gill, David M., Cheng, Heather H., Kessler, Elizabeth R, Chittoria, Namita, Twardowski, Przemyslaw, Vaishampayan, Ulka, Agarwal, Neeraj
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Androgen Antagonists - therapeutic use
Definitive therapy
Humans
Male
mHSPC
Middle Aged
Neoplasm Metastasis
Predictive biomarker
Prognosis
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Radical prostatectomy
Radiotherapy
Retrospective Studies
Survival Rate
Time Factors
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•In men with new metastatic hormone sensitive prostate cancer (mHSPC), time from definitive therapy (DT) to initiation of androgen deprivation therapy (ADT) (
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2019.01.029